Over the forecast period, the global market for complete blood count devices is anticipated to rise at a faster rate due to the rising prevalence of blood infections. For instance, sepsis claims the lives of 11 million people worldwide each year, according to a World Health Organisation report released in September 2020. In addition, sepsis develops when chemicals sent through the bloodstream to treat an infection cause inflammation all across the body. The demand for white blood cell count (WBC or leukocyte count) tests is therefore anticipated to rise as the prevalence of serious blood infections rises. Over the forecast period, product releases by major market players are anticipated to fuel market expansion. A tabletop haematology analyzer called DxH 560 AL, for instance, was introduced by the medical technology business Beckman Coulter in February 2021. It was created to help small to mid-sized diagnostic laboratories with their resource and time restrictions. The DxH 560 AL also produces findings in no more than 60 seconds.
According to Coherent Market Insights, over the projected period (2021-2028), the market for Complete Blood Count Devices is anticipated to grow at a CAGR of 8.3%, reaching an estimated value of US$ 3,642.9 million in 2021.
Market Players in the Complete Blood Count Device Industry:
1. Abbott Laboratories
The company was established in 1888, and its US headquarters are in Chicago, Illinois. It sells wholesome products, name-brand generic drugs, medical equipment, and diagnostics. In January 2022, Abbott revealed the Lingo collection of consumer biowearable sensors. To optimise food and exercise regimens, Lingo collects a range of biological measures. Proclaim Plus from Abbott, a multipurpose spinal cord stimulation device for treating chronic pain, received FDA approval in August 2022.
2. Becton, Dickinson and Company
The company was established in 1897 and has its headquarters in New Jersey, U.S. The business produces and markets reagents, instrument systems, and medical equipment. Moreover, BD offers analytics and consulting services in some areas. BD receives FDA 510(k) clearance in March 2023 for the first-ever high-throughput diagnostic test for infectious vaginitis. BD will launch a High-Throughput Single-Cell Multiomics Platform in February 2023 to broaden the scope of scientific discovery.
